Comparing Vivos Therapeutics (NASDAQ:VVOS) & Iradimed (NASDAQ:IRMD)

Iradimed (NASDAQ:IRMD – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Insider and Institutional Ownership

92.3% of Iradimed shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 42.6% of Iradimed shares are owned by company insiders. Comparatively, 9.6% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Iradimed and Vivos Therapeutics, as provided by MarketBeat.

Iradimed currently has a consensus target price of $60.00, suggesting a potential upside of 21.48%. Vivos Therapeutics has a consensus target price of $6.60, suggesting a potential upside of 188.21%. Given Vivos Therapeutics’ higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Iradimed.

Volatility and Risk

Iradimed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.72, meaning that its share price is 672% more volatile than the S&P 500.

Valuation & Earnings

This table compares Iradimed and Vivos Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Iradimed has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Iradimed and Vivos Therapeutics’ net margins, return on equity and return on assets.

Summary

Iradimed beats Vivos Therapeutics on 11 of the 13 factors compared between the two stocks.

About Iradimed

(Get Free Report)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.